Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

Molecular diagnostics of myeloproliferative neoplasms

(2015) Stephen E. Langabeer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

(2015) D Pietra et al.   LEUKEMIA

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms

(2015) Amy V. Jones et al.   LEUKEMIA RESEARCH

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

(2015) Hans Carl Hasselbalch et al.   MEDIATORS OF INFLAMMATION

A CALR Mutation Preceding BCR-ABL1 in an Atypical Myeloproliferative Neoplasm

(2015) Xénia Cabagnols et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

(2015) P Guglielmelli et al.   Blood Cancer Journal

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients

(2014) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

(2014) A. Tefferi et al.   BLOOD

Presence of calreticulin mutations in JAK2-negative polycythemia vera

(2014) J. Broseus et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

JAK2V617F andCALRmutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort

(2014) Gillian McGaffin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Assessment ofCALRmutations in myelofibrosis patients, post-allogeneic stem cell transplantation

(2014) Karl Haslam et al.   BRITISH JOURNAL OF HAEMATOLOGY

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

(2014) H. Andrikovics et al.   HAEMATOLOGICA

Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis

(2014) J Broséus et al.   LEUKEMIA

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

(2014) X Cabagnols et al.   LEUKEMIA

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact

(2014) A Tefferi et al.   LEUKEMIA

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

(2014) A Tefferi et al.   LEUKEMIA

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

(2014) Bruno Cassinat et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon  -2a

(2013) A. Quintas-Cardama et al.   BLOOD

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression

(2013) C Marty et al.   LEUKEMIA

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

(2013) J V Jovanovic et al.   LEUKEMIA

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

(2013) Thomas Stauffer Larsen et al.   LEUKEMIA RESEARCH

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

(2012) Anthony J. Bench et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden

(2012) Lasse Kjær et al.   PLoS One

Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay

(2011) Thomas Kristensen et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effect of Primer-Template Mismatches on the Detection and Quantification of Nucleic Acids Using the 5′ Nuclease Assay

(2009) Ralph Stadhouders et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD